The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate
In conclusion, our findings indicated that there is insufficient evidence to differentiate the therapeutic efficacy of AA in mPCa based on the presence or absence of ductal features. However, further validation through larger-scale studies is required to substantiate them.
Authors
- Jinge Zhao (ORCID: https://orcid.org/0000-0002-2790-462X)
- Jiayu Liang
- Pengfei Shen (ORCID: https://orcid.org/0000-0002-0370-0411)
- Xu Hu (ORCID: https://orcid.org/0000-0003-4306-4656)
- Ling Nie (ORCID: https://orcid.org/0000-0002-7878-2001)
- Xinyuan Wei (ORCID: https://orcid.org/0000-0001-9337-333X)
- Guangxi Sun (ORCID: https://orcid.org/0000-0003-3719-2643)
- Junru Chen (ORCID: https://orcid.org/0000-0003-4553-6979)
- Hao Zeng (ORCID: https://orcid.org/0000-0003-0818-8151)
- Zhenhua Liu (ORCID: https://orcid.org/0000-0003-1926-6020)
- Ni Chen (ORCID: https://orcid.org/0000-0002-0628-0723)
- Shi Yi-fu
- Xingming Zhang (ORCID: https://orcid.org/0000-0001-8239-5410)
- Fengnian Zhao
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
Publication Details
- Journal
- The Prostate
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1002/pros.24869
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52